TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.

Alexander M M Eggermont et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.